PCVX News and Press, Vaxcyte Inc. From 05/20/25

2025-05-20 16:15:00 ET Summary Janus Henderson Forty Fund returned -8.74% and the Russell 1000® Growth Index returned -9.97%. Stock selection in the consumer discretionary and financials sectors contributed to relative performance, while selection in information technology an...

2025-05-20 09:10:00 ET Summary The Portfolio returned 1.36% (gross) and the MSCI World Health Care Index SM returned 5.29%. Positioning in biotechnology weighed on relative returns, while an underweight to life sciences tools and services contributed to performance. Despite ne...

2025-05-20 04:02:00 ET Summary Janus Henderson Concentrated Growth Managed Account portfolio returned -8.89% (gross) and the Russell 1000® Growth Index returned -10.00%. Stock selection in the consumer discretionary and financials sectors contributed to relative performance, ...

2025-05-20 00:44:00 ET Summary Concentrated All Cap Growth Managed Account returned -9.25% (gross) and the Russell 3000® Growth Index returned -10.05%. Stock selection in the consumer discretionary and financials sectors contributed to relative performance, while selection in...

Aeva Technologies Inc. (AEVA) is expected to report $-0.59 for Q1 2025 Brasilagro Brazilian Agric Real Estate Co Sponsored ADR (Brazil) (LND) is expected to report for Q3 2025 Omron Corporation ADR (OMRNY) is expected to report for Q4 2025 Sezzle Inc. (SEZL) is expected to report $0.3...

2025-05-11 09:56:00 ET Summary Both the fund and benchmark index had negative returns for the quarter. We reduced exposure to artificial intelligence (AI)-related stocks, capital markets and cyclical sectors. This strategy has been further reinforced by ongoing tariff uncertainty....

2025-05-08 04:15:01 ET More on Vaxcyte Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript Vinay Prasad ...

-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, T...

2025-05-07 04:55:00 ET Summary Fidelity® Select Health Care Portfolio employs a sector-based, equity-focused strategy, leveraging fundamental, bottom-up research to build a diversified portfolio of health care companies. The fund underperformed the MSCI health care index in Q...

2025-05-06 14:30:15 ET More on BioNTech, Moderna, etc. BioNTech: mRNA Challenges Amid Regulatory Uncertainty (Rating Downgrade) BioNTech SE (BNTX) Q1 2025 Earnings Call Transcript BioNTech SE 2025 Q1 - Results - Earnings Call Presentation Pfizer, GSK RSV shot...